EU Extends Review Deadline for Solvay Pharmaceuticals, Inc., Abbott Laboratories (JOBS) Deal

Bookmark and Share

Reuters -- EU regulators extended on Friday their review of U.S. drugmaker Abbott Laboratories' (ABT.N) plan to acquire Belgian peer Solvay Pharmaceuticals (SOLB.BR) after Abbott offered remedies to ease competition concerns.

Back to news